Autolus Therapeutics Future Growth
Future criteria checks 2/6
Autolus Therapeutics is forecast to grow earnings and revenue by 52.4% and 48% per annum respectively. EPS is expected to grow by 58.7% per annum. Return on equity is forecast to be -43.5% in 3 years.
Key information
52.4%
Earnings growth rate
58.7%
EPS growth rate
Biotechs earnings growth | 31.0% |
Revenue growth rate | 48.0% |
Future return on equity | -43.5% |
Analyst coverage | Good |
Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 187 | -60 | 1 | 34 | 4 |
12/31/2025 | 72 | -127 | -73 | -101 | 9 |
12/31/2024 | 30 | -174 | -102 | -128 | 9 |
12/31/2023 | 2 | -208 | -157 | -146 | N/A |
9/30/2023 | 6 | -158 | -145 | -135 | N/A |
6/30/2023 | 7 | -155 | -142 | -127 | N/A |
3/31/2023 | 7 | -152 | -133 | -120 | N/A |
12/31/2022 | 6 | -149 | -123 | -112 | N/A |
9/30/2022 | 3 | -164 | -119 | -107 | N/A |
6/30/2022 | 1 | -155 | -119 | -110 | N/A |
3/31/2022 | 2 | -146 | -123 | -116 | N/A |
12/31/2021 | 2 | -142 | -127 | -118 | N/A |
9/30/2021 | 3 | -143 | -149 | -136 | N/A |
6/30/2021 | 3 | -147 | -154 | -141 | N/A |
3/31/2021 | 2 | -145 | -145 | -131 | N/A |
12/31/2020 | 2 | -142 | -132 | -118 | N/A |
9/30/2020 | 2 | -140 | -134 | -123 | N/A |
6/30/2020 | 1 | -130 | -120 | -109 | N/A |
3/31/2020 | 1 | -127 | -113 | -99 | N/A |
12/31/2019 | 3 | -124 | -120 | -101 | N/A |
9/30/2019 | 3 | -104 | -109 | -88 | N/A |
6/30/2019 | 3 | -89 | -93 | -72 | N/A |
3/31/2019 | 3 | -68 | -76 | -61 | N/A |
12/31/2018 | 1 | -58 | -56 | -43 | N/A |
9/30/2018 | 1 | -45 | -41 | -32 | N/A |
6/30/2018 | 1 | -41 | N/A | N/A | N/A |
3/31/2018 | 2 | -38 | N/A | N/A | N/A |
12/31/2017 | 2 | -29 | N/A | N/A | N/A |
9/30/2017 | 2 | -20 | N/A | -16 | N/A |
9/30/2016 | 1 | -13 | N/A | -10 | N/A |
9/30/2015 | 0 | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6A3A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6A3A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6A3A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6A3A's revenue (48% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 6A3A's revenue (48% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6A3A is forecast to be unprofitable in 3 years.